A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 64, Issue 6, Pages e26351
Publisher
Wiley
Online
2016-12-01
DOI
10.1002/pbc.26351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
- (2015) Xiaotu Ma et al. Nature Communications
- Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition
- (2014) J. Irving et al. BLOOD
- A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
- (2014) L. Moreno et al. CLINICAL CANCER RESEARCH
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
- (2013) James Foran et al. Clinical Lymphoma Myeloma & Leukemia
- Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
- (2013) Gertjan J.L. Kaspers et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
- (2012) Qiang Wen et al. CELL
- Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia
- (2012) Vassilios Bavetsias et al. JOURNAL OF MEDICINAL CHEMISTRY
- Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells
- (2012) Aarthi Jayanthan et al. LEUKEMIA & LYMPHOMA
- A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
- (2011) H.- T. Arkenau et al. ANNALS OF ONCOLOGY
- Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia
- (2011) Jennifer E. Podesta et al. LEUKEMIA RESEARCH
- CREBBP mutations in relapsed acute lymphoblastic leukaemia
- (2011) Charles G. Mullighan et al. NATURE
- Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
- (2010) A S Moore et al. LEUKEMIA
- Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
- (2009) S. Meshinchi et al. CLINICAL CANCER RESEARCH
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
- (2009) Richard H. Ko et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
- (2008) M. Case et al. CANCER RESEARCH
- Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†
- (2008) Steven Howard et al. JOURNAL OF MEDICINAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now